Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss.
Journal
Signal transduction and targeted therapy
ISSN: 2059-3635
Titre abrégé: Signal Transduct Target Ther
Pays: England
ID NLM: 101676423
Informations de publication
Date de publication:
22 Jan 2024
22 Jan 2024
Historique:
received:
31
01
2023
accepted:
10
12
2023
revised:
31
10
2023
medline:
22
1
2024
pubmed:
22
1
2024
entrez:
21
1
2024
Statut:
epublish
Résumé
The clinical role and underlying mechanisms of valproic acid (VPA) on bone homeostasis remain controversial. Herein, we confirmed that VPA treatment was associated with decreased bone mass and bone mineral density (BMD) in both patients and mice. This effect was attributed to VPA-induced elevation in osteoclast formation and activity. Through RNA-sequencing, we observed a significant rise in precursor miR-6359 expression in VPA-treated osteoclast precursors in vitro, and further, a marked upregulation of mature miR-6359 (miR-6359) in vivo was demonstrated using quantitative real-time PCR (qRT-PCR) and miR-6359 fluorescent in situ hybridization (miR-6359-FISH). Specifically, the miR-6359 was predominantly increased in osteoclast precursors and macrophages but not in neutrophils, T lymphocytes, monocytes and bone marrow-derived mesenchymal stem cells (BMSCs) following VPA stimulation, which influenced osteoclast differentiation and bone-resorptive activity. Additionally, VPA-induced miR-6359 enrichment in osteoclast precursors enhanced reactive oxygen species (ROS) production by silencing the SIRT3 protein expression, followed by activation of the MAPK signaling pathway, which enhanced osteoclast formation and activity, thereby accelerating bone loss. Currently, there are no medications that can effectively treat VPA-induced bone loss. Therefore, we constructed engineered small extracellular vesicles (E-sEVs) targeting osteoclast precursors in bone and naturally carrying anti-miR-6359 by introducing of EXOmotif (CGGGAGC) in the 3'-end of the anti-miR-6359 sequence. We confirmed that the E-sEVs exhibited decent bone/osteoclast precursor targeting and exerted protective therapeutic effects on VPA-induced bone loss, but not on ovariectomy (OVX) and glucocorticoid-induced osteoporotic models, deepening our understanding of the underlying mechanism and treatment strategies for VPA-induced bone loss.
Identifiants
pubmed: 38246920
doi: 10.1038/s41392-023-01726-8
pii: 10.1038/s41392-023-01726-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Informations de copyright
© 2024. The Author(s).
Références
Silva, A. M. et al. Long noncoding RNAs: a missing link in osteoporosis. Bone Res. 7, 10 (2019).
pubmed: 30937214
pmcid: 6437190
doi: 10.1038/s41413-019-0048-9
Liang, C. et al. Inhibition of osteoblastic Smurf1 promotes bone formation in mouse models of distinctive age-related osteoporosis. Nat Commun 9, 3428 (2018).
pubmed: 30143635
pmcid: 6109183
doi: 10.1038/s41467-018-05974-z
Cummings, S. R. & Melton, L. J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359, 1761–1767 (2002).
pubmed: 12049882
doi: 10.1016/S0140-6736(02)08657-9
Compston, J. E., McClung, M. R. & Leslie, W. D. Osteoporosis. Lancet 393, 364–376 (2019).
pubmed: 30696576
doi: 10.1016/S0140-6736(18)32112-3
Ventura, A. et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132, 875–886 (2008).
pubmed: 18329372
pmcid: 2323338
doi: 10.1016/j.cell.2008.02.019
Brennecke, J., Hipfner, D. R., Stark, A., Russell, R. B. & Cohen, S. M. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113, 25–36 (2003).
pubmed: 12679032
doi: 10.1016/S0092-8674(03)00231-9
Davis, S., Lollo, B., Freier, S. & Esau, C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 34, 2294–2304 (2006).
pubmed: 16690972
pmcid: 1459537
doi: 10.1093/nar/gkl183
Li, C. et al. Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal Transduct Target Ther. 6, 383 (2021).
pubmed: 34753929
pmcid: 8578673
doi: 10.1038/s41392-021-00779-x
Li, D. et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun 7, 10872 (2016).
pubmed: 26947250
pmcid: 4786676
doi: 10.1038/ncomms10872
Yu, L. et al. Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p. J. Extracell Vesicles 10, e12056 (2021).
pubmed: 33489015
pmcid: 7812369
doi: 10.1002/jev2.12056
Kelch, S. et al. miRNAs in bone tissue correlate to bone mineral density and circulating miRNAs are gender independent in osteoporotic patients. Sci. Rep. 7, 15861 (2017).
pubmed: 29158518
pmcid: 5696459
doi: 10.1038/s41598-017-16113-x
Kim, D. K. et al. Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation. Nat Commun 12, 2527 (2021).
pubmed: 33953168
pmcid: 8100305
doi: 10.1038/s41467-021-22754-4
Triantafyllou, N. et al. Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy. J. Neurol. Sci. 290, 131–134 (2010).
pubmed: 20056251
doi: 10.1016/j.jns.2009.12.015
Serin, H. M., Koç, Z. P., Temelli, B. & Esen, İ. The bone mineral content alterations in pediatric patients medicated with levetiracetam, valproic acid, and carbamazepine. Epilepsy Behav. 51, 221–224 (2015).
pubmed: 26298867
doi: 10.1016/j.yebeh.2015.06.025
Li, Y. et al. The promotion of bone regeneration through positive regulation of angiogenic-osteogenic coupling using microRNA-26a. Biomaterials 34, 5048–5058 (2013).
pubmed: 23578559
doi: 10.1016/j.biomaterials.2013.03.052
Zhang, X., Li, Y., Chen, Y. E., Chen, J. & Ma, P. X. Cell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects. Nat Commun 7, 10376 (2016).
pubmed: 26765931
pmcid: 4735608
doi: 10.1038/ncomms10376
Lolli, A. et al. Hydrogel-based delivery of antimiR-221 enhances cartilage regeneration by endogenous cells. J. Control Rel. 309, 220–230 (2019).
doi: 10.1016/j.jconrel.2019.07.040
Hu, Y. et al. Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss. Bioact. Mater. 6, 2905–2913 (2021).
pubmed: 33718671
pmcid: 7917458
Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science. 367, eaau6977 (2020).
pubmed: 32029601
pmcid: 7717626
doi: 10.1126/science.aau6977
Liang, G. et al. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J. Nanobiotechnol. 18, 10 (2020).
doi: 10.1186/s12951-019-0563-2
Yahara, Y. et al. Erythromyeloid progenitors give rise to a population of osteoclasts that contribute to bone homeostasis and repair. Nat Cell Biol. 22, 49–59 (2020).
pubmed: 31907410
pmcid: 6953622
doi: 10.1038/s41556-019-0437-8
Han, K. H. et al. Vascular expression of the chemokine CX3CL1 promotes osteoclast recruitment and exacerbates bone resorption in an irradiated murine model. Bone 61, 91–101 (2014).
pubmed: 24401612
doi: 10.1016/j.bone.2013.12.032
Tsukasaki, M. et al. Stepwise cell fate decision pathways during osteoclastogenesis at single-cell resolution. Nat Metab. 2, 1382–1390 (2020).
pubmed: 33288951
doi: 10.1038/s42255-020-00318-y
Albaghdadi, O., Alhalabi, M. S., Alourfi, Z. & Youssef, L. A. Bone health and vitamin D status in young epilepsy patients on valproate monotherapy. Clin. Neurol. Neurosurg. 146, 52–56 (2016).
pubmed: 27150607
doi: 10.1016/j.clineuro.2016.04.019
Fan, D., Miao, J., Fan, X., Wang, Q. & Sun, M. Effects of valproic acid on bone mineral density and bone metabolism: A meta-analysis. Seizure 73, 56–63 (2019).
pubmed: 31756600
doi: 10.1016/j.seizure.2019.10.017
Fonseca, H., Moreira-Gonçalves, D., Coriolano, H. J. & Duarte, J. A. Bone quality: The determinants of bone strength and fragility. Sports Med. 44, 37–53 (2014).
pubmed: 24092631
doi: 10.1007/s40279-013-0100-7
Kim, H., Lee, Y. D., Kim, H. J., Lee, Z. H. & Kim, H. H. SOD2 and Sirt3 control osteoclastogenesis by regulating mitochondrial ROS. J. Bone Miner. Res. 32, 397–406 (2017).
pubmed: 27540894
doi: 10.1002/jbmr.2974
Zhang, J. et al. Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics 10, 8315–8342 (2020).
pubmed: 32724473
pmcid: 7381741
doi: 10.7150/thno.45922
Pi, H. et al. SIRT3-SOD2-mROS-dependent autophagy in cadmium-induced hepatotoxicity and salvage by melatonin. Autophagy 11, 1037–1051 (2015).
pubmed: 26120888
pmcid: 4590599
doi: 10.1080/15548627.2015.1052208
Pillai, V. B. et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun 6, 6656 (2015).
pubmed: 25871545
doi: 10.1038/ncomms7656
Lee, J. et al. SIRT3 deregulation is linked to mitochondrial dysfunction in Alzheimer’s disease. Aging Cell. 17, e12679 (2018).
pubmed: 29130578
doi: 10.1111/acel.12679
Liu, Y. et al. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities. Theranostics 9, 4648–4662 (2019).
pubmed: 31367247
pmcid: 6643439
doi: 10.7150/thno.35414
He, J. et al. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res. 72, 6393–6402 (2012).
pubmed: 23066034
pmcid: 3525770
doi: 10.1158/0008-5472.CAN-12-2664
Peng, B., Chen, Y. & Leong, K. W. MicroRNA delivery for regenerative medicine. Adv Drug Deliv. Rev. 88, 108–122 (2015).
pubmed: 26024978
pmcid: 4506697
doi: 10.1016/j.addr.2015.05.014
Ibáñez, L. et al. Inflammatory Osteoclasts Prime TNFα-Producing CD4(+) T Cells and Express CX(3) CR1. J. Bone Miner Res. 31, 1899–1908 (2016).
pubmed: 27161765
doi: 10.1002/jbmr.2868
Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29, 341–345 (2011).
pubmed: 21423189
doi: 10.1038/nbt.1807
Tian, Y. et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35, 2383–2390 (2014).
pubmed: 24345736
doi: 10.1016/j.biomaterials.2013.11.083
Ghosh, R., Singh, L. C., Shohet, J. M. & Gunaratne, P. H. A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials 34, 807–816 (2013).
pubmed: 23111335
doi: 10.1016/j.biomaterials.2012.10.023
Jeyaram, A. et al. Enhanced loading of functional miRNA Cargo via pH gradient modification of extracellular vesicles. Mol. Ther. 28, 975–985 (2020).
pubmed: 31911034
doi: 10.1016/j.ymthe.2019.12.007
Zhang, D. et al. Exosome-mediated small RNA delivery: A novel therapeutic approach for inflammatory lung responses. Mol. Ther. 26, 2119–2130 (2018).
pubmed: 30005869
pmcid: 6127502
doi: 10.1016/j.ymthe.2018.06.007
Kooijmans, S. A. A. et al. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J. Control Release 172, 229–238 (2013).
pubmed: 23994516
doi: 10.1016/j.jconrel.2013.08.014
Lamichhane, T. N. et al. Oncogene knockdown via active loading of small RNAs into extracellular vesicles by sonication. Cell Mol. Bioeng. 9, 315–324 (2016).
pubmed: 27800035
doi: 10.1007/s12195-016-0457-4
Garcia-Martin, R. et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. Nature 601, 446–451 (2022).
pubmed: 34937935
doi: 10.1038/s41586-021-04234-3
Song, H. et al. Reversal of osteoporotic activity by endothelial cell-secreted bone targeting and biocompatible exosomes. Nano Lett. 19, 3040–3048 (2019).
pubmed: 30968694
doi: 10.1021/acs.nanolett.9b00287
Boluk, A. et al. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res. 50, 93–97 (2004).
pubmed: 15082034
doi: 10.1016/j.phrs.2003.11.011
Sato, Y. et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57, 445–449 (2001).
pubmed: 11502911
doi: 10.1212/WNL.57.3.445
Verrotti, A., Agostinelli, S., Coppola, G., Parisi, P. & Chiarelli, F. A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy. Eur. J. Neurol. 17, 232–237 (2010).
pubmed: 19682062
doi: 10.1111/j.1468-1331.2009.02773.x
Seymour, R. A., Smith, D. G. & Turnbull, D. N. The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients. J. Clin. Periodontol 12, 413–419 (1985).
pubmed: 3926831
doi: 10.1111/j.1600-051X.1985.tb01377.x
Gilles, P., Alliët, P., Bruneel, E. & Raes, M. Effect of valproate on bone mineral density. J. Pediatr. 128, 441 (1996).
pubmed: 8774525
doi: 10.1016/S0022-3476(96)70311-6
Tao, Z. S., Zhou, W. S., Xu, H. G. & Yang, M. Intermittent administration sodium valproate has a protective effect on bone health in ovariectomized rats. Eur. J. Pharmacol. 906, 174268 (2021).
pubmed: 34166702
doi: 10.1016/j.ejphar.2021.174268
Rocha, S., Ferraz, R., Prudêncio, C., Fernandes, M. H. & Costa-Rodrigues, J. Differential effects of antiepileptic drugs on human bone cells. J. Cell Physiol. 234, 19691–19701 (2019).
pubmed: 30941778
doi: 10.1002/jcp.28569
Akshaya, N. et al. Valproic acid, A potential inducer of osteogenesis in mouse mesenchymal stem cells. Curr. Mol. Pharmacol 14, 27–35 (2021).
pubmed: 32660413
doi: 10.2174/1874467213666200713102410
La Noce, M. et al. Cytoplasmic interactions between the glucocorticoid receptor and HDAC2 regulate osteocalcin expression in VPA-treated MSCs. Cells 8, 217 (2019).
pubmed: 30841579
pmcid: 6468918
doi: 10.3390/cells8030217
Zaidi, M. Skeletal remodeling in health and disease. Nat Med. 13, 791–801 (2007).
pubmed: 17618270
doi: 10.1038/nm1593
Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337–342 (2003).
pubmed: 12748652
doi: 10.1038/nature01658
Tanaka, S., Nakamura, K., Takahasi, N. & Suda, T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev. 208, 30–49 (2005).
pubmed: 16313339
doi: 10.1111/j.0105-2896.2005.00327.x
Andreev, D. et al. Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin. J. Clin. Invest. 130, 4811–4830 (2020).
pubmed: 32773408
pmcid: 7456234
doi: 10.1172/JCI134214
Faccio, R. et al. Vav3 regulates osteoclast function and bone mass. Nat Med. 11, 284–290 (2005).
pubmed: 15711558
doi: 10.1038/nm1194
Tse, M. T. Bone diseases: SEMA3A strikes a balance in bone homeostasis. Nat. Rev Drug Discov. 11, 442 (2012).
pubmed: 22596250
doi: 10.1038/nrd3759
Hayashi, M. et al. Osteoprotection by semaphorin 3A. Nature 485, 69–74 (2012).
pubmed: 22522930
doi: 10.1038/nature11000
Bellini, G. et al. PKCβII-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity. Pharmacol Res. 115, 267–274 (2017).
pubmed: 27919827
doi: 10.1016/j.phrs.2016.11.039
Sun, W. et al. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov. 2, 16015 (2016).
pubmed: 27462462
pmcid: 4886818
doi: 10.1038/celldisc.2016.15
Ling, W. et al. Mitochondrial Sirt3 contributes to the bone loss caused by aging or estrogen deficiency. JCI Insight 6 (2021).
Li, N. et al. Inhibition of Sirtuin 3 prevents titanium particle-induced bone resorption and osteoclastsogenesis via suppressing ERK and JNK signaling. Int. J. Biol. Sci. 17, 1382–1394 (2021).
pubmed: 33867853
pmcid: 8040473
doi: 10.7150/ijbs.53992
Gao, J. et al. SIRT3/SOD2 maintains osteoblast differentiation and bone formation by regulating mitochondrial stress. Cell Death Differ. 25, 229–240 (2018).
pubmed: 28914882
doi: 10.1038/cdd.2017.144
Li, Q. et al. Sirt3 mediates the benefits of exercise on bone in aged mice. Cell Death Differ. 30, 152–167 (2023).
pubmed: 36153410
doi: 10.1038/s41418-022-01053-5
Guo, Y. et al. Sirt3-mediated mitophagy regulates AGEs-induced BMSCs senescence and senile osteoporosis. Redox Biol. 41, 101915 (2021).
pubmed: 33662874
pmcid: 7930642
doi: 10.1016/j.redox.2021.101915
Wu, Q. J. et al. The sirtuin family in health and disease. Signal Transduct Target Ther. 7, 402 (2022).
pubmed: 36581622
pmcid: 9797940
doi: 10.1038/s41392-022-01257-8
Zhang, B. et al. A novel nano delivery system targeting different stages of osteoclasts. Biomater. Sci. 10, 1821–1830 (2022).
pubmed: 35244664
doi: 10.1039/D2BM00076H
Kimiz-Gebologlu, I. & Oncel, S. S. Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J. Control Release 347, 533–543 (2022).
pubmed: 35597405
doi: 10.1016/j.jconrel.2022.05.027
Xie, H. et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med. 20, 1270–1278 (2014).
pubmed: 25282358
pmcid: 4224644
doi: 10.1038/nm.3668
Lötvall, J. et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J. Extracell Vesicles 3, 26913 (2014).
pubmed: 25536934
doi: 10.3402/jev.v3.26913